Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Brian P. McDonough, MD, FAAFP
Matthew Galsky, MD
DESTINY-Breast11: Clinically Relevant Adverse Events
Charles E. Geyer Jr., MD, FACP
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
A.J. Gelderblom, MD, PhD
Beyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Jacob Sands, MD
Julia Rotow, MD
Xiuning Le, MD, PhD
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Pavani Chalasani, MD, MPH
Erica L. Mayer, MD, MPH
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Ryan Quigley
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.